Publications by authors named "Helene Duret"

Claim this Profile
T
Type I NKT-cell-mediated TNF-α is a positive regulator of NLRP3 inflammasome priming.
Melvyn T Chow, Helene Duret, Daniel M Andrews, Christelle Faveeuw, Andreas Möller

Eur J Immunol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.
Yuting Ma, Stephen R Mattarollo, Sandy Adjemian, Heng Yang, Laetitia Aymeric, Helene Duret

Cancer Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.
Annamaria Biroccio, Julien Cherfils-Vicini, Adeline Augereau, Sébastien Pinte, Serge Bauwens, Helene Duret

Nat Cell Biol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.
Yuting Ma, Sandy Adjemian, Stephen R Mattarollo, Takahiro Yamazaki, Laetitia Aymeric, Helene Duret

Immunity· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.
Stephen R Mattarollo, Kim Steegh, Ming Li, Helene Duret, Shin Foong Ngiow

Immunol Cell Biol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases.
Melvyn T Chow, Jaclyn Sceneay, Christophe Paget, Christina S F Wong, Helene Duret

Cancer Res· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma.
Christophe Paget, Helene Duret, Shin Foong Ngiow, Maya Kansara, David M Thomas

Oncoimmunology· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
Stephen R Mattarollo, Alison C West, Kim Steegh, Helene Duret, Christophe Paget

Blood· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state.
Michele W L Teng, Matthew D Vesely, Helene Duret, Nicole McLaughlin, Jennifer E Towne

Cancer Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.
Inge Verbrugge, Jim Hagekyriakou, Leslie L Sharp, Mara Galli, Alison West, Hélène Duret

Cancer Res· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of γδ T cells in α-galactosylceramide-mediated immunity.
Christophe Paget, Melvyn T Chow, Helene Duret, Stephen R Mattarollo, Mark J Smyth

J Immunol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.
Stephen R Mattarollo, Sherene Loi, Helene Duret, Yuting Ma, Laurence Zitvogel

Cancer Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
John Stagg, Upulie Divisekera, Helene Duret, Tim Sparwasser, Michele W L Teng

Cancer Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
John Stagg, Sherene Loi, Upulie Divisekera, Shin Foong Ngiow, Helene Duret

Proc Natl Acad Sci U S A· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases.
Michele W L Teng, Bianca von Scheidt, Helene Duret, Jennifer E Towne, Mark J Smyth

Cancer Res· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis